{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T14:52:51Z","timestamp":1753887171428,"version":"3.41.2"},"reference-count":38,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The study aimed to analyze the mortality and leading causes of death associated with Sj\u00f6gren\u2019s syndrome (SS) in the United States (US) between 1999 and 2020 using a multicause approach. We analyzed mortality based on SS as the cause-of-death. Using mortality rates, number of deaths, and historical trends, we examined sex, age of death, comparisons of SS- and polymyalgia rheumatica-related deaths (multiple cause-of-death) in the last 20 years, changes in the ranking of causes of death when SS was the underlying cause-of-death (UCD) in the first and last 5 years of the last 20 years, and the number of deaths and standardized mortality (per 100,000 people) when SS combined with interstitial lung disease (ILD) or tumor was the multiple cause-of-death. An SS-standardized mortality trend chart and a trend line were created. In 22 years, the total number of SS-related deaths in the US was 7,817, including 7,016 women. When SS was the UCD and non-UCD, the standardized ratios of female-to-male deaths (per 100,000 people) were approximately 4.6\u201313:1 and 6.8\u201319.6:1, respectively. SS-related deaths were more common in people aged &gt;60 years and concentrated in patients aged 60\u201379. In cases where SS and polymyalgia rheumatica were the multiple cause-of-death, the number of deaths and age-standardized mortality of SS and polymyalgia rheumatica increased, although lower in SS than in polymyalgia rheumatica. Regarding SS as the UCD, heart disease ranks first. Concerning the number of deaths and standardized mortality in the first (1999\u20132003) and second (2016\u20132020) 5 years, when SS-ILD and SS combined with tumors were the multiple causes of death, the number increased in the second 5 years compared to that in the first 5 years. When SS combined with COVID-19 was the multiple cause-of-death, 73 deaths occurred, comprising 64 females and 9 males. Death predominance was observed among women and patients aged 60\u201379 years with SS. Although the SS-standardized mortality rate was low, an increasing trend was observed. When SS was the primary cause-of-death, heart disease remained primarily involved, followed by malignant neoplasms. The number of patients with SS-ILD and SS combined with tumors in the past 22 years and the standardized mortality rate after 5 years increased compared with those of the previous 5 years. Concurrent SS and COVID-19 may be related to the increased SS deaths.<\/jats:p>","DOI":"10.1515\/med-2023-0829","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T06:52:02Z","timestamp":1698735122000},"source":"Crossref","is-referenced-by-count":1,"title":["Mortality associated with Sj\u00f6gren\u2019s syndrome in the United States in the 1999\u20132020 period: A multiple cause-of-death study"],"prefix":"10.1515","volume":"18","author":[{"given":"Rongxiu","family":"Huo","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, Guangxi Academy of Medical Sciences, The People\u2019s Hospital of Guangxi Zhuang Autonomous Region , Nanning City , 530016 , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinxiang","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Guangxi Academy of Medical Sciences, The People\u2019s Hospital of Guangxi Zhuang Autonomous Region , Nanning City , 530016 , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinying","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Guangxi Academy of Medical Sciences, The People\u2019s Hospital of Guangxi Zhuang Autonomous Region , Nanning City , 530016 , China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2023,10,30]]},"reference":[{"key":"2023103019320641884_j_med-2023-0829_ref_001","doi-asserted-by":"crossref","unstructured":"Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F, et al. Epidemiology of primary Sj\u00f6gren\u2019s syndrome: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(11):1983\u20139. 10.1136\/annrheumdis-2014-205375.","DOI":"10.1136\/annrheumdis-2014-205375"},{"key":"2023103019320641884_j_med-2023-0829_ref_002","doi-asserted-by":"crossref","unstructured":"Brito-Zer\u00f3n P, Kostov B, Solans R, Fraile G, Su\u00e1rez-Cuervo C, Casanovas A, et al. Systemic activity and mortality in primary Sj\u00f6gren syndrome: predicting survival using the EULAR-SS disease activity index (ESSDAI) in 1045 patients. Ann Rheum Dis. 2016;75(2):348\u201355. 10.1136\/annrheumdis-2014-206418.","DOI":"10.1136\/annrheumdis-2014-206418"},{"key":"2023103019320641884_j_med-2023-0829_ref_003","unstructured":"Thomas E, Symmons DP, Brewster DH, Black RJ, Macfarlane GJ. National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study. J Rheumatol. 2003;30(5):958\u201365."},{"key":"2023103019320641884_j_med-2023-0829_ref_004","doi-asserted-by":"crossref","unstructured":"Nannini C, Jebakumar AJ, Crowson CS, Ryu JH, Matteson EL. Primary Sjogren\u2019s syndrome 1976-2005 and associated interstitial lung disease: a population-based study of incidence and mortality. BMJ Open. 2013;3(11):e003569. 10.1136\/bmjopen-2013-003569.","DOI":"10.1136\/bmjopen-2013-003569"},{"key":"2023103019320641884_j_med-2023-0829_ref_005","doi-asserted-by":"crossref","unstructured":"Singh AG, Singh S, Matteson EL. Rate, risk factors and causes of mortality in patients with Sj\u00f6gren\u2019s syndrome: a systematic review and meta-analysis of cohort studies. Rheumatol (Oxf). 2016;55(3):450\u201360. 10.1093\/rheumatology\/kev354.","DOI":"10.1093\/rheumatology\/kev354"},{"key":"2023103019320641884_j_med-2023-0829_ref_006","doi-asserted-by":"crossref","unstructured":"Mahmood SB, Nelson E, Padniewski J, Nasr R. Polymyalgia rheumatica: an updated review. Cleve Clin J Med. 2020;87(9):549\u201356. 10.3949\/ccjm.87a.20008.","DOI":"10.3949\/ccjm.87a.20008"},{"key":"2023103019320641884_j_med-2023-0829_ref_007","doi-asserted-by":"crossref","unstructured":"Raheel S, Shbeeb I, Crowson CS, Matteson EL. Epidemiology of polymyalgia Rheumatica 2000-2014 and examination of incidence and survival trends over 45 years: a population-based study. Arthritis Care Res (Hoboken). 2017;69(8):1282\u20135. 10.1002\/acr.23132.","DOI":"10.1002\/acr.23132"},{"key":"2023103019320641884_j_med-2023-0829_ref_008","doi-asserted-by":"crossref","unstructured":"Salvarani C, Macchioni P, Zizzi F, Mantovani W, Rossi F, Castri C, et al. Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy. Arthritis Rheum. 1991;34(3):351\u20136. 10.1002\/art.1780340313.","DOI":"10.1002\/art.1780340313"},{"key":"2023103019320641884_j_med-2023-0829_ref_009","doi-asserted-by":"crossref","unstructured":"Gao H, Sun Y, Zhang XY, Xie L, Zhang XW, Zhong YC, et al. Characteristics and mortality in primary Sj\u00f6gren syndrome-related interstitial lung disease. Med (Baltim). 2021;100(35):e26777. 10.1097\/MD.0000000000026777.","DOI":"10.1097\/MD.0000000000026777"},{"key":"2023103019320641884_j_med-2023-0829_ref_010","doi-asserted-by":"crossref","unstructured":"Brito-Zer\u00f3n P, Kostov B, Fraile G, Caravia-Dur\u00e1n D, Maure B, Rasc\u00f3n FJ, et al. Characterization and risk estimate of cancer in patients with primary Sj\u00f6gren syndrome. J Hematol Oncol. 2017;10(1):90. 10.1186\/s13045-017-0464-5.","DOI":"10.1186\/s13045-017-0464-5"},{"key":"2023103019320641884_j_med-2023-0829_ref_011","doi-asserted-by":"crossref","unstructured":"Kov\u00e1cs L, Szodoray P, Kiss E. Secondary tumours in Sj\u00f6gren\u2019s syndrome. Autoimmun Rev. 2010;9(4):203\u20136. 10.1016\/j.autrev.2009.07.002.","DOI":"10.1016\/j.autrev.2009.07.002"},{"key":"2023103019320641884_j_med-2023-0829_ref_012","doi-asserted-by":"crossref","unstructured":"Theander E, Manthorpe R, Jacobsson LT. Mortality and causes of death in primary Sj\u00f6gren\u2019s syndrome: a prospective cohort study. Arthritis Rheum. 2004;50(4):1262\u20139. 10.1002\/art.20176.","DOI":"10.1002\/art.20176"},{"key":"2023103019320641884_j_med-2023-0829_ref_013","doi-asserted-by":"crossref","unstructured":"Strangfeld A, Sch\u00e4fer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology alliance physician-reported registry. Ann Rheum Dis. 2021;80(7):930\u201342. 10.1136\/annrheumdis-2020-219498.","DOI":"10.1136\/annrheumdis-2021-220134"},{"key":"2023103019320641884_j_med-2023-0829_ref_014","doi-asserted-by":"crossref","unstructured":"Brito-Zer\u00f3n P, Kostov B, Fraile G, Caravia-Dur\u00e1n D, Maure B, Rasc\u00f3n FJ, et al. Characterization and risk estimate of cancer in patients with primary Sj\u00f6gren syndrome. J Hematol Oncol. 2017;10(1):90. 10.1186\/s13045-017-0464-5.","DOI":"10.1186\/s13045-017-0464-5"},{"key":"2023103019320641884_j_med-2023-0829_ref_015","doi-asserted-by":"crossref","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, Bombardieri S, Bootsma H, De Vita S, D\u00f6rner T, et al. EULAR recommendations for the management of Sj\u00f6gren\u2019s syndrome with topical and systemic therapies. Ann Rheum Dis. 2020;79(1):3\u201318. 10.1136\/annrheumdis-2019-216114.","DOI":"10.1136\/annrheumdis-2019-216114"},{"key":"2023103019320641884_j_med-2023-0829_ref_016","doi-asserted-by":"crossref","unstructured":"Sambataro G, Ferro F, Orlandi M, Sambataro D, Torrisi SE, Quartuccio L, et al. Clinical, morphological features and prognostic factors associated with interstitial lung disease in primary Sj\u04e7gren\u2019s syndrome: A systematic review from the Italian Society of Rheumatology. Autoimmun Rev. 2020;19(2):102447. 10.1016\/j.autrev.2019.102447.","DOI":"10.1016\/j.autrev.2019.102447"},{"key":"2023103019320641884_j_med-2023-0829_ref_017","unstructured":"World Health Organization. Manual of the International Statistical Classification of Diseases, Injuries and Causes of Death. Vol. 1. Geneva: World Health Organization; 1997. Ninth Revision."},{"key":"2023103019320641884_j_med-2023-0829_ref_018","doi-asserted-by":"crossref","unstructured":"Horvath IF, Szanto A, Papp G, Zeher M. Clinical course, prognosis, and cause of death in primary Sj\u00f6gren\u2019s syndrome. J Immunol Res. 2014;2014:647507. 10.1155\/2014\/647507.","DOI":"10.1155\/2014\/647507"},{"key":"2023103019320641884_j_med-2023-0829_ref_019","doi-asserted-by":"crossref","unstructured":"Westhoff G, Zink A. Epidemiologie des prim\u00e4ren Sj\u00f6gren-syndroms [Epidemiology of primary Sj\u00f6rgren\u2019s syndrome]. Z Rheumatol. 2010;69(1):41\u20139. 10.1007\/s00393-009-0518-3.","DOI":"10.1007\/s00393-009-0518-3"},{"key":"2023103019320641884_j_med-2023-0829_ref_020","doi-asserted-by":"crossref","unstructured":"Alamanos Y, Tsifetaki N, Voulgari PV, Venetsanopoulou AI, Siozos C, Drosos AA. Epidemiology of primary Sj\u00f6gren\u2019s syndrome in north-west Greece, 1982-2003. Rheumatol (Oxf). 2006;45(2):187\u201391. 10.1093\/rheumatology\/kei107.","DOI":"10.1093\/rheumatology\/kei107"},{"key":"2023103019320641884_j_med-2023-0829_ref_021","doi-asserted-by":"crossref","unstructured":"Nannini C, Jebakumar AJ, Crowson CS, Ryu JH, Matteson EL. Primary Sjogren\u2019s syndrome 1976-2005 and associated interstitial lung disease: a population-based study of incidence and mortality. BMJ Open. 2013;3(11):e003569. 10.1136\/bmjopen-2013-003569.","DOI":"10.1136\/bmjopen-2013-003569"},{"key":"2023103019320641884_j_med-2023-0829_ref_022","doi-asserted-by":"crossref","unstructured":"Lee YK, Ahn GY, Lee J, Shin JM, Lee TH, Park DJ, et al. Excess mortality persists in patients with rheumatoid arthritis. Int J Rheum Dis. 2021;24(3):364\u201372. 10.1111\/1756-185X.14058.","DOI":"10.1111\/1756-185X.14058"},{"key":"2023103019320641884_j_med-2023-0829_ref_023","unstructured":"Meo SA, Klonoff DC, Akram J. Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19. Eur Rev Med Pharmacol Sci. 2020;24(8):4539\u201347. 10.26355\/eurrev_202004_21038."},{"key":"2023103019320641884_j_med-2023-0829_ref_024","doi-asserted-by":"crossref","unstructured":"Hutchings MI, Truman AW, Wilkinson B. Antibiotics: past, present and future. Curr Opin Microbiol. 2019;51:72\u201380. 10.1016\/j.mib.2019.10.008.","DOI":"10.1016\/j.mib.2019.10.008"},{"key":"2023103019320641884_j_med-2023-0829_ref_025","doi-asserted-by":"crossref","unstructured":"Totura AL, Bavari S. Broad-spectrum coronavirus antiviral drug discovery. Expert Opin Drug Discov. 2019;14(4):397\u2013412. 10.1080\/17460441.2019.1581171.","DOI":"10.1080\/17460441.2019.1581171"},{"key":"2023103019320641884_j_med-2023-0829_ref_026","doi-asserted-by":"crossref","unstructured":"Larsen FS. Artificial liver support in acute and acute-on-chronic liver failure. Curr Opin Crit Care. 2019;25(2):187\u201391. 10.1097\/MCC.0000000000000584.","DOI":"10.1097\/MCC.0000000000000584"},{"key":"2023103019320641884_j_med-2023-0829_ref_027","doi-asserted-by":"crossref","unstructured":"Flament T, Bigot A, Chaigne B, Henique H, Diot E, Marchand-Adam S. Pulmonary manifestations of Sj\u00f6gren\u2019s syndrome. Eur Respir Rev. 2016;25(140):110\u201323. 10.1183\/16000617.0011-2016.","DOI":"10.1183\/16000617.0011-2016"},{"key":"2023103019320641884_j_med-2023-0829_ref_028","doi-asserted-by":"crossref","unstructured":"Sun G, Fosb\u00f8l EL, Yafasova A, Faurschou M, Lindhardsen J, Torp-Pedersen C, et al. Long-term risk of heart failure and other adverse cardiovascular outcomes in primary Sj\u00f6gren\u2019s syndrome. J Intern Med. 2023 Apr;293(4):457\u201369. 10.1111\/joim.13595.","DOI":"10.1111\/joim.13595"},{"key":"2023103019320641884_j_med-2023-0829_ref_029","doi-asserted-by":"crossref","unstructured":"Kim YJ, Choe J, Kim HJ, Song JW. Long-term clinical course and outcome in patients with primary Sj\u00f6gren syndrome-associated interstitial lung disease. Sci Rep. 2021;11(1):12827. 10.1038\/s41598-021-92024-2.","DOI":"10.1038\/s41598-021-92024-2"},{"key":"2023103019320641884_j_med-2023-0829_ref_030","doi-asserted-by":"crossref","unstructured":"Roca F, Dominique S, Schmidt J, Smail A, Duhaut P, L\u00e9vesque H, et al. Interstitial lung disease in primary Sj\u00f6gren\u2019s syndrome. Autoimmun Rev. 2017;16(1):48\u201354. 10.1016\/j.autrev.2016.09.017.","DOI":"10.1016\/j.autrev.2016.09.017"},{"key":"2023103019320641884_j_med-2023-0829_ref_031","doi-asserted-by":"crossref","unstructured":"Palm O, Garen T, Berge Enger T, Jensen JL, Lund MB, Aal\u00f8kken TM, et al. Clinical pulmonary involvement in primary Sjogren\u2019s syndrome: prevalence, quality of life and mortality--a retrospective study based on registry data. Rheumatol (Oxf). 2013;52(1):173\u20139. 10.1093\/rheumatology\/kes311.","DOI":"10.1093\/rheumatology\/kes311"},{"key":"2023103019320641884_j_med-2023-0829_ref_032","doi-asserted-by":"crossref","unstructured":"Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med. 2005;165(20):2337\u201344. 10.1001\/archinte.165.20.2337.","DOI":"10.1001\/archinte.165.20.2337"},{"key":"2023103019320641884_j_med-2023-0829_ref_033","doi-asserted-by":"crossref","unstructured":"Quartuccio L, Isola M, Baldini C, Priori R, Bartoloni Bocci E, Carubbi F, et al. Biomarkers of lymphoma in Sj\u00f6gren\u2019s syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study. J Autoimmun. 2014;51:75\u201380. 10.1016\/j.jaut.2013.10.002.","DOI":"10.1016\/j.jaut.2013.10.002"},{"key":"2023103019320641884_j_med-2023-0829_ref_034","doi-asserted-by":"crossref","unstructured":"Retamozo S, Gheitasi H, Quartuccio L, Kostov B, Corazza L, Bov\u00e9 A, et al. Cryoglobulinaemic vasculitis at diagnosis predicts mortality in primary Sj\u00f6gren syndrome: analysis of 515 patients. Rheumatol (Oxf). 2016;55(8):1443\u201351. 10.1093\/rheumatology\/kew194.","DOI":"10.1093\/rheumatology\/kew194"},{"key":"2023103019320641884_j_med-2023-0829_ref_035","doi-asserted-by":"crossref","unstructured":"Gottenberg JE, Seror R, Miceli-Richard C, Benessiano J, Devauchelle-Pensec V, Dieude P, et al. Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sj\u00f6gren\u2019s syndrome. Data at enrollment in the prospective ASSESS cohort. PLoS One. 2013;8(5):e59868. 10.1371\/journal.pone.0059868.","DOI":"10.1371\/journal.pone.0059868"},{"key":"2023103019320641884_j_med-2023-0829_ref_036","doi-asserted-by":"crossref","unstructured":"Brito-Zer\u00f3n P, Melchor S, Seror R, Priori R, Solans R, Kostov B, et al. SARS-CoV-2 infection in patients with primary Sj\u00f6gren syndrome: characterization and outcomes of 51 patients. Rheumatol (Oxf). 2021;60(6):2946\u201357. 10.1093\/rheumatology\/keaa748.","DOI":"10.1093\/rheumatology\/keaa748"},{"key":"2023103019320641884_j_med-2023-0829_ref_037","doi-asserted-by":"crossref","unstructured":"Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859\u201366. 10.1136\/annrheumdis-2020-217871.","DOI":"10.1136\/annrheumdis-2020-217871"},{"key":"2023103019320641884_j_med-2023-0829_ref_038","unstructured":"Walsh SJ, DeChello LM. Excess autoimmune disease mortality among school teachers. J Rheumatol. 2001;28(7):1537\u201345."}],"container-title":["Open Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/med-2023-0829\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/med-2023-0829\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T06:52:21Z","timestamp":1698735141000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/med-2023-0829\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,1]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,10,30]]},"published-print":{"date-parts":[[2023,10,30]]}},"alternative-id":["10.1515\/med-2023-0829"],"URL":"https:\/\/doi.org\/10.1515\/med-2023-0829","relation":{},"ISSN":["2391-5463"],"issn-type":[{"type":"electronic","value":"2391-5463"}],"subject":[],"published":{"date-parts":[[2023,1,1]]},"article-number":"20230829"}}